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ABSTRACT 
The vast majority of cancer exhibit increased glucose uptake and glycolysis regardless of oxygen 
availability. This metabolic shift leads to an enhanced production of lactic acid that, in turn, leads to the 
acidification of the extracellular pH (pHe) which represents a characteristic hallmark of tumour 
microenvironment. Dysregulated tumour pHe and up-regulated glucose metabolism are therefore tightly 
linked and their relative assessment may be very useful for pursuing a better understanding of the underlying 
biology. Here we investigated in vivo and non-invasively the correlation between tumour 18F-FDG uptake 
and extracellular pH values in a breast HER2+ tumour murine model. Tumour extracellular pH and perfusion 
have been assessed by acquiring MRI-CEST (Chemical Exchange Saturation Transfer) images on a 3T 
scanner, upon the intravenous administration of a pH-responsive contrast agent (iopamidol). Static PET 
images were recorded immediately after MRI acquisitions to quantify the extent of 18F-FDG uptake. First, 
we demonstrated accurate tumour pHe measurements that were able to report on induced pHe changes. 
Combined PET and MRI-CEST images reported complementary spatial information of the altered glucose 
metabolism. A significant inverse correlation was found between extracellular tumour pH and 18F-FDG 
uptake (%ID/g: r = -0.552, P<0.01; SUV: r = -0.587, P<0.01). Furthermore, for the first time, we 
demonstrated in vivo that tumours with high 18F-FDG uptake show higher extracellular acidosis. These 
results suggest that merging the information between 18F-FDG-uptake and extracellular pH mapping 
represent a valuable tool for an improved imaging-based characterisation of tumour microenvironment. 
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INTRODUCTION 
Solid tumours are characterized by a highly heterogeneous and acidic microenvironment. The combination 
of poor vascular perfusion, regional hypoxia and high rates of glucose metabolism are responsible for 
generating extracellular acidosis in solid tumours (1). In fact, tumour cells rely mostly on the conversion of 
glucose into lactate rather than mitochondrial oxidation for energy production, even in the presence of well-
oxygenated conditions (Warburg effect) (2). This metabolic switch toward a glycolytic phenotype occurs 
early in cancers, during the avascular phase, thus promoting the adaptation of the tumour cells to an acidic 
microenvironment. Extracellular tumour acidosis is an indicator of bad prognosis and it is relevant to 
facilitate tumour migration and invasion by the degradation of the extracellular matrix (3). Tumour acidosis 
has also been linked to multi-drug resistance due to the neutralization of weak base chemotherapeutic drugs, 
which makes the drugs less efficient to cross the cellular membrane (4). It follows that the possibility of 
measuring precise extracellular tumour pH (pHe) at high spatio-temporal resolution is considered of great 
interest in both preclinical and clinical settings, offering selective and specific strategies for developing new 
treatments for solid tumours (5, 6). Moreover, the development quantitative imaging techniques and novel 
imaging biomarkers is considered a key research priority in the medical imaging community (7, 8).  
Currently the gold standard for tumour detection in clinical settings is represented by [18F]2-fluoro-2-deoxy-
D-glucose (18F-FGD) as it acts as a metabolic tracer in positron emission tomography (PET) to report on the 
over-expression/up-regulation of glucose transporters (9). 18F-FDG enters the tumour cells and accumulates 
because it cannot be metabolised beyond the first phosphorylation step. In spite of the complexity of the 18F-
FDG PET methodology, 18F-FDG quickly became a biomarker of outstanding importance in oncology and it 
is used daily in the clinical settings as a surrogate marker of pathological response and survival for a vast 
array of cancers (10). Despite this valuable functional information, PET imaging suffers for a limited spatial 
resolution that limits the information about tumour heterogeneity (11). Conversely, the superb spatial 
resolution of magnetic resonance imaging (MRI) allows accurate assessments of the heterogeneity of the 
tumour lesion. Several MRI-based approaches have been proposed for measuring tumour pH in vivo (12-14). 
Among them, the method based on chemical exchange saturation transfer (CEST) has recently gained  great 
attention (15). This MRI approach relies on the pH-dependence of the prototropic exchange rates and the 
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exchange of magnetization between mobile protons and water is exploited for detecting low-concentration 
molecules. As a source of mobile protons, either endogenous amide-containing molecules (16, 17), or 
exogenous pH-responsive contrast agents (CAs) can be used (18-20). Notably, within the latter class, it has 
been shown that the FDA-approved iodinated contrast media for x-ray computed tomography (CT) imaging 
can be exploited for MRI-CEST pH imaging both at preclinical and clinical level (19, 21-24). 
Currently, there is a great expectation that the combination of PET and MRI techniques in the acquisition of 
images of the same anatomical region may open new horizons for an improved characterisation of tumour 
microenvironment, merging functional information delivered by PET with morphologic and functional 
imaging attainable by MRI. The physical integration of PET and MRI systems has already been achieved 
both for clinical use as well as for animal studies (25, 26). Therefore, by integrating MRI/PET information, 
the advantages of each imaging modality for assessing key features of the pathology can be exploited (27, 
28). In addition, reduction of ionizing radiation dose, in comparison to PET/ CT systems, gives further 
support to consider PET/MRI approaches especially in longitudinal studies. 
In general, one would expect that tumour extracellular pH and 18F-FDG uptake are linked as the lowering of 
pH in the extracellular region is, first of all, the result of an increased production of glycolytic byproducts, 
lactate and H+, which are released by cancer cells in order to maintain physiological intracellular pH 
homeostasis (29). It is therefore important to elucidate, for each tumour phenotype, whether and to what 
extent, 18F-FDG uptake and pHe can be closely-lined biomarkers of the altered glycolytic rate. 
Unfortunately, despite aerobic glycolysis and increased extracellular acidification are recognised as 
hallmarks of solid tumours, no clear evidence of this relationship has been reported so far in vivo. In 
addition, it would be desirable to develop imaging approaches that can be translatable to the clinics. Here we 
assess the potential of MRI-CEST tumour pHe mapping at a clinical field of 3T by using the pH-responsive 
contrast agent iopamidol. We show that the combination of 18F-FDG PET uptake and iopamidol-based MRI-
CEST pH mapping can provide new insights for an improved characterisation of tumour metabolism and 
microenvironment. 
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MATERIALS AND METHODS 
Materials 
The following materials were used in this study: RPMI1640 medium, fetal bovine serum, glutamine, 
penicillin and streptomycin (Lonza Sales AG, Verviers, Belgium); Iopamidol (Bracco Imaging Spa, 
Colleretto Giacosa, Italy); 18F-FDG (Advanced Acceleration Applications, Colleretto Giacosa, Italy); 
phosphate-saline buffer (Sigma Aldrich, Milano, Italy); goat serum (Sigma Aldrich, Milano, Italy); O.C.T. 
compound (Tissue Tek®, Sakura Finetek, Tokyo, Japan); primary antibody rat anti-mouse CD31 (BD 
Pharmigen, Milano, Italy); secondary antibody Alexa Fluor-568 goat anti-rat  (Life Technologies, Monza, 
Italy); Hoescht33258 (Sigma Aldrich, Milano, Italy); mounting medium Fluoroshield (Sigma Aldrich, 
Milano, Italy). 
 
Tumour Model 
TS/A is an aggressive and poorly immunogenic cell line first established from the in vivo transplant of a 
moderately differentiated mammary adenocarcinoma that arose spontaneously in a 20-month-old 
multiparous BALB/c mouse (30). TS/A cells were maintained in RPMI 1640 medium supplemented with 
10% fetal bovine serum, 2mM glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin and preserved 
in a humified incubator at 37°C with 5% CO2. For the preparation of the TS/A tumour model, 2.5x105 cells 
in RPMI medium were inoculated subcutaneously into both the left and right hind limb of BALB/c mice, 
respectively. Tumour growth was allowed to grow to 3 to 5 weeks into tumours of suitable volume that was 
precisely measured by MRI. To investigate the relationship between glucose uptake and tumour pHe, a first 
cohort of TS/A tumour bearing mice were imaged by sequential MRI and PET imaging (n=23 tumours). An 
additional cohort of TS/A bearing mice were split into two groups, with the first group receiving 200 mM 
bicarbonated water ad libitum for five days to modulate tumour pHe (n=6), and the second group receiving 
regular drinking water (n=6). All animal procedures and husbandry were performed in accordance with the 
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European Communities Council Directive (86/609/EEC) and approved by the Committee on Animal Care 
and Use of our University. 
 
MRI-CEST experiments 
MR images were acquired on a 3T Bruker Biospec (Bruker, Ettlingen Germany) scanner equipped with a 30 
mm quadrature RF coil. Mice were anesthetised with isoflurane vaporised with O2. Isoflurane was used at 
3.0% for induction and at 1.0%–2.0% for maintenance. A single T2-weighted axial slice crossing the centre 
of the tumours was acquired with TR = 4 sec, TE = 3.7 ms, NA =1, slice thickness = 1.5 mm, FOV = 30x30 
mm, matrix size = 256x256, which yielded an in-plane resolution of 117 µm. CEST images were acquired 
with continuous wave (CW) RF irradiation (3 µT for 5 sec) by using a single-shot RARE sequence (TR = 6.0 
sec, effective TE = 8.7ms, centric encoding, slice thickness = 1.5 mm, FOV = 30 mm, matrix size = 96x96, 
in-plane spatial resolution = 312 µm, NA = 1) with 46 frequency offsets unevenly distributed from -10 to 10 
ppm relative to the water resonance, with the acquisition time for each Z-spectrum being 4 min 36s. The 
contrast agent (iopamidol) was injected intravenously into the tail vein at a dose of 4 g I/kg b.w. for tumour 
pH mapping. 
 
PET imaging and analysis 
Following the MRI,  a dedicated animal bed was designed to immediately shift the mice to the PET scanner 
(for a similar approach see (31)), where static acquisitions were performed after an uptake time of 45 min 
and a 18F-FDG injected dose of 15±3 MBq. MRI and PET/CT images were coregistered by fiducial markers. 
Mice were anesthetized with isoflurane vaporized with O2. Isoflurane was used at 3.0% for induction and at 
1.0%–2.0% for maintenance. Mice were imaged using the trimodality PET/SPECT/CT scanner Triumph 
(Trifoil imaging, Chatsworth, CA, USA). 18F-FDG was supplied by Advanced Accelerator Appplications 
(AAA, Colleretto Giacosa, Italy). Mice were kept fasting overnight before intravenously 18F-FDG injection. 
PET images were acquired 45 min after tracer injection followed by a CT acquisition (80 kVp, 110 mA, 
magnification 2.25). PET data were reconstructed using 2D-Maximum Likelihood Expectation 
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Maximization (MLEM) algorithm with 10 iterations and were corrected for tracer decay and for photon 
attenuation. Analysis of PET images and co-registration to MR images were performed using PMOD 
software (http://www.pmod.com). A volume-of-interest (VOI) approach was used to determine the amount 
of radiotracer uptake and to determine regional values for the maximal percentage injected dose per cubic 
centimeter (%ID/cm3). The SUV and SUVmax were obtained using the following formula: SUV = mean 
activity in the region of interest (MBq/g)/(injected dose [MBq]/body weight) and SUVmax: maximum 
activity in the region of interest (MBq/g)/(injected dose [MBq]/body weight). 
 
CEST image analysis 
All data analysis was performed using custom-written scripts in Matlab (Mathworks, Natick, MA, USA). All 
Z-spectra were interpolated, on a voxel-by-voxel basis, by smoothing splines, to identify the right position of 
the bulk water signal, for B0 inhomonogeneity correction. The interpolated Z-spectrum was shifted so that 
the bulk water resonance corresponds to the zero frequency and CEST contrast was quantified at a specific 
offset of interest (i.e. Δω= +4.2/+5.5 ppm) using the asymmetry analysis: 
𝑆𝑆𝑆𝑆 = 𝑆𝑆−Δ𝜔𝜔 − 𝑆𝑆+Δ𝜔𝜔
𝑆𝑆0
 
Where S±Δω is the water signal intensity in the presence of a saturation pulse at offset ±Δω and S0 is water 
signal intensity in the absence of a saturation pulse.  
For in vivo images, difference contrast maps (ΔST%) were calculated by subtracting the ST% contrast after 
iopamidol injection from the ST% contrast before the injection on a per voxel basis in order to reduce the 
confounding effect of the endogenous contributions. ST% maps were calculated for both the frequency 
offsets of 4.2 and 5.5 ppm, by subtracting the corresponding pre-contrast ST% maps. A threshold value of 
2% was set, based on the ΔST variations between multiple pre-contrast ST% maps (ca. 0.8% at 4.2 ppm and 
1.7% at 5.5 μT, respectively) to discriminate between enhancing and not-enhancing pixels. Ratiometric 
values were calculated by ratioing the difference contrast maps at the two different frequency offsets of 4.2 
and 5.5 ppm. Only those voxels showing an increase of ST contrast higher than 2%, in comparison to pre-
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contrast ST% map were included for the following pH calculations. pH maps were obtained by back-
calculating the pH values from the obtained ratiometric values on a voxel-by-voxel basis according to the 
corresponding pH calibration curve of Fig. 1c. Extravasation (perfusion) maps were determined as the 
percentage of pixels showing a ΔST% higher than 2% inside the whole tumour region. The higher the 
percentage of pixels showing an increase of the ST% contrast above the threshold, the higher the 
corresponding extravasation parameter. 
 
Histologic analysis 
After images acquisition, mice were sacrificed and tumour tissues excised. Tumours were embedded in 
O.C.T. compound and frozen in liquid nitrogen. Cryo-sections slices of 5 µm of thickness were subsequently 
cut and fixed in ice-cold acetone for 10 minutes and blocked with PBS containing 10% goat serum for 1 hour 
at room temperature. The sections were incubated with anti-mouse CD31 (1:200) overnight and then with 
secondary antibody (1:500) for 1 hour at room temperature. After nuclei staining with Hoescht 33258 for 10 
minutes at room temperature, sections were mounted with Fluoroshield. Images were acquired with a 
motorised z-focus confocal microscope (Leica Microsystems, Milano, Italy). 
 
Statistical analysis 
Statistical evaluations were performed using GraphPad Prism software (GraphPad, San Diego, CA, USA). 
Correlations among MRI-CEST (using pH, ΔST% and extravasation fraction) and 18F-FDG-PET (using 
%ID/g, SUV and SUVmax) values and tumour volumes were calculated using the Pearson product-moment 
coefficient. Correlations were interpreted using the guidelines from Cohen (32), with absolute correlations of 
<0.3 considered weak, 0.3–0.5 moderate, and 0.5–1.0 strong. Statistical significance was assessed at a level 
of P less than 0.05. 
 
RESULTS 
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The CEST method for mapping pH using iopamidol (a widely used x-ray contrast agent) was recently 
proposed and applied in vivo on a scanner operating at 7 T (18). As our project aims at exploring routes to 
transfer preclinical results to clinical applications it was deemed of interest to work at 3T that is the magnetic 
field strength of the currently available PET-MRI scanners. Iopamidol MRI-CEST pH-sensitivity was then 
first evaluated at 3T and 310K on a phantom consisting of tubes filled with aqueous solutions of Iopamidol 
(30mM) at different pH, from 6.0 to 7.4. The Saturation Transfer (ST%) values to the bulk water signal were 
measured when the off-set of the irradiation fields was set at the exchanging amide proton resonances, i,e, at 
4.2 ppm and at 5.5 ppm, respectively. Fig. 1a shows representative Z-spectra at pH of 6, 6.5 and 7. Fig. 1b 
shows CEST effect (ST%) measured at 4.2 (circles) and 5.5 (squares) ppm, respectively, upon applying a 
saturation rf field of 3 µT for 5s. ST% values steadily increase with pH for both amide proton pools. The 
differences in the pH dependence of ST% observed for the absorptions at 4.2 and 5.5 ppm enables the set-up 
of the ratiometric method for pH quantification yielding ratios that range from 1.1 to 1.9 on going from pH 6 
to 7.4, respectively (Fig. 1c). The accuracy of the pH-CEST method was evaluated by comparing the pH 
values calculated on the basis of the observed ST% ratios and the pH values measured by a pH-meter. pH 
values determined from the MRI-CEST approach  strongly correlates with the calibrated pH (Pearson’s r = 
0.993, P<0.001), showing that a good pH accuracy is feasible at a clinical magnetic field. The pH MRI 
precision decreased with pH, as the standard deviation of calculated pH was higher at lower pH, likely due to 
the decreased prototropic exchange rates at lower pH that results in smaller ST% effects (Fig. 1d). 
MRI-CEST pHe maps were acquired in vivo in HER2 positive tumour bearing mice upon the intravenous 
administration of iopamidol at clinical magnetic field (3T). CEST contrast was quantified by measuring 
difference ST% maps (ΔST% = ST%post – ST%pre iopamidol injection) in order to reduce confounding 
effects from baseline ST contrast arising from tumour endogenous components. It has been found that 
iopamidol is sufficiently well detected at this field, with an average ST% increase from baseline values of 3-
5% at 4.2 ppm and of 2-4% at 5.5 ppm, respectively (Fig. 2e). ΔST% maps showed that the increase in ST% 
contrast is highly heterogeneous in the ROI, indicating that not all the voxels of the tumour region are 
vascularised, or are leaky, to a similar extent (Fig. 2a and Fig. 2b). As a consequence, the not homogeneous 
distribution of iopamidol is itself a read-out of the extent of perfusion in the tumour microenvironment and it 
directly informs about the tumour heterogeneity in terms of vascular permeability (Fig. 2d). Overall, about 
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50-60% of the total pixels showed an increase in ΔST% values above the detection thresholds. For these 
pixels the corresponding tumour extracellular pH values have been computed (Fig. 2c). All the investigated 
HER2 positive breast cancer mice showed extracellular acidifications, with mean tumour extracellular pH 
values in the range 6.6-7.0. Variations in pHe values within the tumours covered a range of ~0.6-0.8 pH units 
(Fig. 2c), but no marked general trend (e.g. from the core to the rim) was observed. 
Validation of the proposed CEST-pH mapping approach in assessing pHe changes was performed in tumours 
bearing mice fed with bicarbonated water. The average pHe in control mice was significantly more acidic 
than the average pHe of tumours in mice having received 5 days of bicarbonated water (6.74 ±0.07 versus 
7.01 ±0.08, respectively; P<0.001, Fig. 3a). Representative tumour pHe maps show an increase of less acidic 
pHe voxels in mice drinking water containing sodium bicarbonate, in comparison to control mice (Figs. 3b 
and 3c). 
Fig. 4 shows one example of a mouse bearing subcutaneous HER2+ allograft tumours, which was 
sequentially imaged by a 3T MRI and a PET scanner. After the acquisition of tumour pHe map upon 
iopamidol injection (Fig. 4a), the 18F-FDG tracer was administered and static PET images were acquired, 
clearly showing 18F-FDG uptake in the tumour regions (Fig. 4b). The area of higher FDG uptake in the 
tumour corresponds to lower pHe values, whereas the area of lower FDG uptake corresponds to less acidic 
tumour microenvironment. This can also be seen in the histogram analysis of the corresponding areas, 
showing pHe distribution values shifted to more acidic values for the tumour regions with an increased 
glucose uptake (Fig. 4c). In the analyzed tumors, the 18F-FDG average %ID/g ranged from 1.5 to 5.5% 
(mean 3.2 ±1.1%), the SUV ranged from 0.4 and 1 (mean 0.7 ±0.2) and the SUVmax ranged from 0.5 to 1.3 
(mean 0.9 ±0.3).  
Finally, the relationship between the glycolytic rate and tumour acidosis was assessed between the estimates 
obtained from 18F-FDG-PET and MRI-CEST pH in 23 matched PET-MRI tumour images (Table 1 and Fig. 
5). PET derived parameters appear related to the tumour volume (Pearson’s correlation coefficients %ID/g: r 
= -0.671, P<0.01; SUV: r = -0.710, P<0.01, SUVmax: r = -0.764, P<0.01; TLG: r = 0.467, P< 0.01). A 
significantly strong correlation was found between 18F-FDG uptake related parameters and CEST-pH 
measurements (%ID/g: r = -0.552, P<0.01, SUV: r = -0.587, P<0.01 and SUVmax: r=-0.525, P<0.01).  
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Insights on the heterogeneous tumour vascularisation have been gained ex-vivo by immunofluorescence 
staining for CD-31 which showed an extensive tumour vascular heterogeneity (Supplementary Fig. S1) 
analogous to that measured by CEST extravasation maps (Fig. 2d). 
 
DISCUSSION 
To the best of our knowledge, this is the first study aimed at comparing 18F-FDG uptake and extracellular pH 
in tumours by means of combined PET and MRI-CEST measurements. The herein reported results show that 
this approach is feasible and it may be a valuable tool for non-invasive imaging-based metabolic 
phenotyping of tumours. 
18F-FDG-PET imaging is a well established, clinically used modality in the diagnosis and management of 
various malignancies, showing that the vast majority of cancers exhibit significantly increased glucose 
uptake compared with normal tissue. The increased glycolysis of tumour cells, even in the presence of 
adequate oxygen supplies, results in a significant decrease of the extracellular pH. There is now god 
evidence that the increased consumption of glucose is instrumental for the production of H+, which promotes 
tumour cell migration, invasion and angiogenesis (33). Increased glucose consumption and increased acid 
production are therefore tightly correlated and their relative assessment may be very useful for pursuing a 
better understanding of the underlying biology. The herein reported results show that a good correlation 
exists between 18F-FDG-PET uptake (associated with the metabolic characteristics of the tumour) and MRI-
CEST extracellular pH (associated with the acidification of the extracellular tumour microenvironment). In 
the investigated breast tumour model, we observed a significant inverse correlation between 18F-FDG uptake 
and extracellular pH (Fig. 5). Moreover, it has been found that tumour regions with higher extracellular 
acidosis correspond to tumour regions with high 18F-FDG uptake (Fig. 4c). Notably, the observed behaviour 
is in agreement with the expectation that glycolysis and production of acids are increased in tumours cells 
compared to normal cells (34). Previous studies investigated the relationship between tumour acidosis and 
lactate production, but no spatial correlations have been observed, despite large amount of lactate are 
excreted by glycolytic cancer cells (13, 35). One possible explanation is related to the role of lactate in 
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tumour metabolism, for which recent findings have shown that is not merely the final product of glycolysis, 
but it can be re-used as an energetic fuel for oxidative metabolism (36). Therefore, the lack of a direct 
correlation between lactate and acidosis may not be unexpected accordingly to the differential use of this 
molecule. 
Interest in measuring and in vivo imaging of tumour pH has driven the development of pH-sensing contrast 
agents, in particular in the MRI field, in order to obtain pH maps of both extracellular and intracellular 
compartments (5, 14, 37). MRI-CEST based approaches have recently emerged as a powerful tool for 
imaging pH, thanks to the development of ratiometric methods that rule out the need to know the contrast 
agent concentration (18, 22, 38-40). In addition, our approach, in comparison to others, allow measurements 
of tumour pHe with high spatial resolution, high temporal resolution and can be applied to tumours as small 
as few mm3 (41). Cancers display various kinds of heterogeneity, including metabolism and vasculature, but 
many approaches are limited to volume-averaged tumour pHe measurements that cannot account for tumour 
heterogeneity (42). In contrast, CEST-pH imaging allows the non-invasive characterisation of in vivo pHe 
distribution on a voxel-basis. Owing to the high spatial resolution of MRI-CEST images, the pHe values 
distribution within a tumour ROI can also be analysed by conventional histogram analysis as an improved 
method to assess pHe heterogeneity (Fig. 4c). Our technique, owing to the injection of an extracellular agent, 
allows also the assessment of the extravasation fraction, a surrogate marker of tumour perfusion. We 
observed inhomogeneous iopamidol distribution within the tumours, likely reflecting low and high 
vascularised area in the heterogeneous tumour region, as confirmed by immunohistochemical analysis of 
tumour vascularisation (Supplementary Fig. S1). Similar findings have also been reported upon comparing 
several iodinated contrast media, in the same breast tumour model (43). It was found that the heterogeneous 
distribution of x-ray radiographic molecules in the extracellular-extravascular space of the tumour, as 
measured by the CEST approach, correlates well with the extravasation quantified by the CT approach, 
hence dependent on tumour vascular volume and vessel permeability characteristics. 
Besides the capability of measuring tumour pHe, novel proposed approaches should be able to provide a 
precise read-out of pH changes. It is known that administering sodium bicarbonate significantly alter tumour 
pHe (44). We achieved similar results with mice drinking ad libitum bicarbonate water (200 mM): the 
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average tumour pHe in the non-modulated mice was significantly more acidic than the average pHe of 
tumours in mice having received 5 days of bicarbonated water (Fig. 3). Thus our approach is enough 
sensitive to detect small pHe changes upon pharmacological treatment, thus opening the possibility to exploit 
pH imaging as a surrogate marker of therapeutic response to novel anticancer therapies (45).  
Overall, as the information provided by each readout (18F-FDG uptake and pH) reflect a different aspect of 
the same altered metabolic behaviour, the combination of the two metrics should results in a synergic action 
of the two modalities. Furthermore, the availability of combined PET/MRI scanners for the simultaneous 
acquisition of molecular and functional data with high temporal and spatial fusion accuracy are already 
available both at preclinical and clinical level, thus making pH mapping and 18F-FDG uptake a powerful tool 
for tumour metabolic phenotyping (46, 47). However, despite the extracellular acidity is considered a 
distinctive feature of cancer, the exploitation of pH sensing agents has been commonly limited to preclinical 
studies, since no investigations on their safety profiles have been reported so far for their use in patients. On 
the contrary, the method presented here uses a pH-responsive agent that is a FDA approved contrast media 
within the CT modality, hence a fast translation to patients for assessing tumour pH is expected; in fact, an 
early phase clinical trial to estimate tumour extracellular pH in women with early stage breast cancer is 
currently ongoing (48). Moreover, analogues approaches based on other (radio)-tracers specific for 
physiological processes such as proliferation, hypoxia and amino acid transporters may likely widen the 
impact of hybrid PET/MRI measurements for tumour characterisation (49, 50).  
One of the limitations of our study is that pH and 18F-FDG measurements have been performed on the same 
animal but not simultaneously on the same scanner, therefore the time gap between the two measures may 
likely introduce some bias on the metrics that we are comparing. However, the aim of this study was the 
correlation between the mean tumour values of 18F-FDG uptake and pHe, and further combined MRI/PET 
studies will allow investigating the true temporal and spatial correlation between the two estimates. 
 
CONCLUSION 
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In summary, the herein reported results, although limited to a breast cancer murine model, have shown the 
correlation between tumour extracellular pH and 18F-FDG uptake. MRI-CEST tumour pH mapping provides 
significant, complementary information to 18F-FDG-PET in the characterisation of the cancer phenotype, as 
the high spatial resolution associated to MR images provides additional insights on tumour perfusion 
heterogeneity. Furthermore, as the increased acidification of the extracellular tumour microenvironment can 
be targeted with specific novel therapies, this combined imaging approach could be exploited as a novel 
imaging biomarker of therapeutic response. 
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TABLES 
Table 1. Pearson correlation coefficients for [18F]-FDG PET, CEST-pH data and tumour volume 
Measures Volume %ID/g SUV SUVmax pH Extravasation  
Volume 1       
%ID/g -0.671** 1      
SUV -0.710**  0.959** 1     
SUVmax -0.764**  0.932**  0.952** 1    
pH  0.519**  -0.552** -0.587** -0.525** 1   
Extravasation    0.143   0.283   0.208    0.082 -0.025 1  
Abbrevations: SUV = mean standard uptake value; SUVmax= maximum SUV. 
All correlations were calculated using independent data points from 23 tumours. Intermodality correlations are shown in 
boldface type. 
*p<0.05 **p < 0.01 
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FIGURE LEGENDS 
Fig. 1 Iopamidol pH responsiveness at 3T. (a) Z-spectra of PBS buffered solutions of iopamidol (30 mM) at 
three representative pH values  of 6, 6.5 and 7 (B1=3 µT, RF saturation time = 5s, 310K). (b) CEST ratio 
(ST%) calculated from the asymmetry analysis as a function of pH. (c) Plot of the ratiometric (RST) values in 
the pH range from 6 to 7.4. (d) Comparison of pH values determined by the iopamidol MRI-CEST method 
versus pH-meter measured values. 
Fig. 2 Representative MRI-CEST images of a breast tumour bearing mouse showing difference ST% 
contrast map (calculated as ST% after injection – ST% before injection) at 4.2 ppm (a) and at 5.5 ppm (b), 
respectively, pH map (c) and extravasation map (d) overimposed onto the anatomical T2w-image. Pre- and 
post- iopamidol injection ST% curves from ROIs including the two tumours are shown in (e). 
Fig. 3 Average tumour pHe values in mice drinking natural or bicarbonated water showing a statistically 
significant increase of tumour pHe after 5 days of bicarbonated water (a). Representative tumour pHe maps 
showing higher percentage of pixels with more acidic values for control mice (b) in comparison to sodium 
bicarbonate treated ones (c). 
Fig. 4 Combined (a) PET/CT and (b) MRI T2w/CEST pH images of a representative TS/A tumour bearing 
mouse with different 18F-FDG uptake levels: PET images showing tumour area with higher 18F-FDG uptake 
levels correspond to pH maps with lower tumour extracellular pH values. Distribution histogram plots (c) of 
MRI-CEST pH values within two ROIs designed in the PET image (b) for tumour regions characterised by 
high (ROI 1) and low (ROI 2) FDG uptake values. ROI1 shows more acidic values in comparison to ROI2 
(mean pH = 6.5 ±0.3 and 6.8 ±0.5 for ROI1 and ROI2, respectively). 
Fig. 5 Scatterplots with regression line (solid line) showing correlations between multi-modality PET/MRI 
calculated estimates. (a) %ID/g 18F-FDG uptake as a function of extracellular tumour pH. (b) SUV 18F-FDG 
uptake as a function of extracellular tumour pH. (c) SUVMAX 18F-FDG uptake as a function of extracellular 
tumour pH. 
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